Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) causes substantial morbidity afflicting approximately 10% of adult males. Treatment is often empirical and ineffective since the etiology is unknown. Other prostate and genitourinary diseases have genetic components suggesting that CP/CPPS may also be influenced by genetic predisposition. We recently reported a highly polymorphic short tandem repeat (STR) locus near the phosphoglycerate kinase gene within Xq11^13. Because this STR is in a region known to predispose towards other prostate diseases, we compared STR polymorphisms in 120 CP/CPPS patients and 300 control blood donors. Nine distinct allele sizes were detected, ranging from 8 to 15 repeats of the tetrameric STR plus a mutant allele (9.5) with a six base deletion in the flanking DNA sequence. The overall allele size distribution in the CP/CPPS patients differed from controls (Chi-square = 19.252, df = 8, P = 0.0231). Frequencies of two specific alleles, 9.5 and 15, differed significantly in CP/CPPS vs. control subjects and allele 10 differed with marginal significance. Alleles 9.5 and 10 were both more common in CP/CPPS patients than controls while allele 15 was less common. These observations suggest that Xq11^13 may contain one or more genetic loci that predispose toward CP/CPPS. Further investigations involving family studies, larger patient populations, and other control groups may help elucidate this potential genetic predisposition in CP/CPPS. ß
Introductioǹ
Prostatitis' is the diagnosis given to many men who present with pain referable to the lower genitourinary tract and perineum [1^3] . In 1978^79, prostatitis accounted for approximately 25% of outpatient visits for genitourinary complaints [4] . Of 12 760 000 visits to urologists in 1991, 5.3% were for prostatitis. Prostatitis ranked fourth of 20 diagnoses given for visits to urologists [4] . Prostatitis was a diagnosis in 2^7 million visits annually from 19909 6, including 8% of visits to urologists and 1% of all primary care visits [5, 6] . A survey of male residents found that the overall prevalence rate of a physicianassigned diagnosis of prostatitis was 9%, similar to rates of ischemic heart disease and diabetes based on a random sampling survey of residents in Olmsted County, MN, USA [7] . Depending on their age, men with a previous diagnosis of prostatitis had a 20^50% risk for recurrent episodes.
The current consensus classi¢cation of prostatitis syndromes includes four categories: acute bacterial prostatitis, chronic bacterial prostatitis, asymptomatic in£ammatory prostatitis, and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) [8, 9] . Acute bacterial prostatitis presents with acute symptoms of bacterial urinary tract infection caused by the standard uropathogens. Patients may also have systemic symptoms of infection, but most respond promptly to appropriate antibacterial therapy. Recurrent episodes of bacteriuria caused by the same uropathogen constitute a hallmark of chronic bacterial prostatitis. Between episodes of bacteriuria, careful culture methods can prove that the focus of infection is the prostate gland. Patients with chronic bacterial prostatitis are unusual, constituting less than 7% of patients attending our chronic prostatitis clinic [10] . Asymptomatic in£ammatory prostatitis is diagnosed during evaluation of other conditions, for example based on ¢nding in£ammatory in¢ltrates in a prostate biopsy obtained for evaluation of possible prostate cancer. CP/CPPS is the most common type of chronic prostatitis accounting for more than 90% of patients with symptoms. Patients su¡er debilitating symptoms, but they do not have bacteriuria or clear evidence of infection with the possible exception of recent PCR-based ¢ndings [11] . Because we have limited understanding of the causes of this syndrome, therapy is entirely empirical and often unsatisfactory.
Many patients ask if their family history is an important determinant of their own risk for developing prostate disease. Genetic background is important in prostate cancer that has been associated with a number of genes on the X chromosome [12^18] . In contrast to the well-described pedigrees of patients with familial prostate cancer, we have limited information about the potential genetic factors associated with CP/CPPS.
Genetic predisposition is implicated in many urogenital diseases including kidney disease [19^22] . Similar genetic factors may in£uence the risk for bacterial urinary tract infections characteristic of acute and chronic bacterial prostatitis in men. In women, the risk of recurrent urinary tract infection clearly re£ects genetic background, e.g. blood group antigen and secretor status [23^26] . Thus, it is reasonable to expect that genetic factors may be important in CP/ CPPS.
Both embryonic and later development of the prostate require presence of androgens and androgen receptors (ARs). Interestingly, the X chromosome contains a polymorphic gene for the AR that is located near one of the putative prostate cancer loci [12^16, 18,27^29] . Although literature searches revealed no reports of genetic predisposition to CP/ CPPS, 23% of patients attending our clinic reported a history of ¢rst-degree male relatives with prostatitis compared to a rate of 9% described in the overall male population [7] . Those histories did not exclude father/son relationships. The high rate of prostatitis among relatives of patients was similar to the experience of the Prostatitis Foundation, where a 20% rate was reported among respondents to an internet survey (http://prostatitis.org/aboutpf.html). Patient interviews suggested in£uence from the maternal lineage (http://prostatitis.freeservers.com). We identi¢ed a polymorphic short tandem repeat (STR) on the X chromosome that allowed us to evaluate if there is a potential genetic predisposition to CP/ CPPS.
Phosphoglycerate kinase (PGK; ATP:3-phospho-D-glycerate 1-phosphotransferase, EC 2.7.2.3) is a metabolic housekeeping enzyme located within Xq11^Xq13. The PGK gene is closely linked [30] to AR within a region implicated in a number of Xlinked urologic disorders. These disorders include: familial predisposition to prostate cancer [14^16], androgen insensitivity [17, 31] and perineal hypospadias [32, 33] . Initially, we identi¢ed a highly polymorphic STR DNA sequence near the PGK gene [34, 35] . In over 500 people tested, 10 distinct alleles were detected with frequencies ranging from 2% to 38%. Since the locus is X-linked, heterozygosities must be measured in women, and heterozygosity is generally s 80%. Herein, we report our ¢ndings comparing the distributions of STR alleles in patients with CP/CPPS to a control population. Our ¢ndings are consistent with the clinical suggestion that there may indeed be an inherited predisposition for some men to develop CP/CPPS.
Materials and methods

CP/CPPS patient population and clinical evaluation
Subjects with CP/CPPS were recruited from patients attending the University of Washington Prostatitis Clinic following a protocol approved by the University of Washington Human Subjects Committee. No subject had taken antimicrobial agents for 6 weeks prior to enrollment and patients with documentation of bacteriuria were excluded. Following a standardized history and physical examination, we obtained specimens for urethral Gram stain and cultures for Neisseria gonorrhoea, Chlamydia trachomatis, genital mycoplasmas, and Trichomonas vaginalis [36, 37] . Each patient had a uro£ow study and residual urine determination by ultrasound to exclude signi¢cant structural or functional abnormalities of the lower urinary tract. We also excluded potential subjects who had uropathogens localized to the prostate by the four-glass urine test (chronic bacterial prostatitis), urethritis ( s 5 leukocytes/400U ¢eld on the Gram-stained urethral smear), or positive urethral cultures for C. trachomatis or T. vaginalis.
CP/CPPS patient specimens
Each CP/CPPS patient underwent prostatic biopsy using a perineal, rather than a transrectal, approach to prevent microbial contamination. Biopsies were obtained by the double-needle biopsy technique described previously [11] . Control samples were obtained of the perineal skin surface and of peri-prostatic tissues. Prostate biopsies were sent to the PCR laboratory in sterile containers within 30 min of collection.
Control population
Patients attending the general hospital clinics were sampled on three consecutive days in batches of approximately 100. Patient data were screened to determine ethnic information, sex, diagnoses, and clinics attended. Male samples in the control group were not used if there was a history of prostate disease in their medical records. While representative of our general clinical population, we cannot exclude unreported histories or predispositions toward prostate disease among members of the control group. Female blood samples were included in the control group since, for the X-linked PGK STR, female samples have twice the information content of male samples. Also, female samples would have arrived at the clinic for reasons other than prostate disease making these a useful sampling of the gene pool within our clinical patient population. Since men inherit their X chromosomes from their mothers, there is no reason a priori to expect population di¡erences comparing male and female PGK STR distributions and no differences were found in the present study.
Stoppered tubes containing ethylenediaminetetraacidic acid and disposed blood drawn from 300 men and women were obtained from the University of Washington Medical Center Central Processing facility. Blood was drawn between 8 and 48 h prior to DNA isolation. DNA was extracted from 300 control blood samples (132 male, 168 female) and prostatic biopsy specimens of 120 prostatitis patients.
PCR assays
Based on the reported PGK £anking DNA sequence [35] PCR primers were constructed to amplify the PGK 3P STR. The primer sequences used in the current study were: PGK11: 5P-TGGGCAACAGT-GAGACTCT-3P; PGK12: 5P-CAACTACAGAAC-AGCAGGTA-3P. Thermal cycles were: 94³C for 5 min, then 35 cycles of 94³C for 1 min, 62³C for 1 min, 72³C for 1 min followed by extension at 72³C for 7 min. PCR bu¡er consisted of 10 mM Tris^HCl (pH 8.3) 50 mM KCl, and 1.0 mM MgCl 2 . Initially, MgCl 2 concentrations were varied over the range 0.5^5 mM, with 1.0 mM proving optimal. Annealing temperatures were initially varied from 60³C to 70³C, with 62³C proving optimal. Taq polymerase (Perkin-Elmer; Norwalk, CT, USA, 5 U/100 Wl of reaction) was used as the thermostable enzyme.
Allele size determination
We synthesized £uorescent PCR primers complementary to an STR in the 3P £ank of the PGK1 gene. The ampli¢ed products were electrophoresed, sized and sequenced using a LiCor automated sequencer (Genereader, 4,000; Lincoln, NE, USA). Allelic sizing at the PGK STR locus, coupled with highthroughput £uorescent PCR product detection, facilitated rapid typing of samples. Approximately 50 PCR products could be electrophoresed and detected in a little over 30 min. Electrophoretic gels in this system have been reloaded up to ¢ve times with little deterioration in the signal-to-noise ratio. Fluorescent detection of PCR products was made possible by incorporating 1^2 pmol IRD41 (absorbance maximum 795 nm, £uorescence maximum 833 nm; Eastman Kodak, Rochester, NY, USA)-labeled PGK12 primer synthesized at LiCor (Lincoln, NE, USA).
Results
Polymorphism and hemizygosity
Nine distinct alleles were detected including eight Fig. 1 . Schematic diagram of the PGK1 STR region of the X chromosome. Top, the Xq12^Xq13 region of the X chromosome. DXS991, GeneMap'99 anchor marker; MTHFD, 5,10-methylenetetrahydrofolate dehydrogenase; GTF1A1, general transcription factor IIA ; AR, androgen receptor gene; DXS983, anchor marker; LDLR, low density lipoprotein receptor; PGK1, phosphoglycerate kinase 1 gene; DXS995, anchor marker; TBG, thyroxin-binding globulin. There are some uncertainties in gene order in this region of the X chromosome. The inset shows a digital image of a LiCor £uorescent gel. L, ladders containing all known PGK1 STR alleles. Ladders were run in every fourth lane for the 420 subjects studied. Single-band PCR products for male subjects were sized by comparison with the known ladder band DNA fragments.
based on variations in the number of TATC repeats ( Figs. 1 and 2 ). Since the PGK1 STR is located on the X chromosome, males exhibit one allele each, while women each exhibit two alleles. Alleles were named for the number of STR repeats they contained, or for their size. The allele frequency distributions are shown in the Table 1 .
None of the male tissue or blood samples demonstrated more than a single PGK STR allele. A single allele per male sample was consistent with the X chromosomal location of the PGK STR and also suggested that cross-contamination of these samples was infrequent since cross-contamination would lead to multiple allele sizes appearing in male samples.
Cases vs. control distributions
The median allele size among 120 CP/CPPS cases was 11 (range 8^14). This was lower than the median allele size of 12 (range 8^15) among the 300 control subjects (Mann^Whitney U = 14912, P = 0.006). The overall distribution of alleles ( Fig. 1) was also di¡er-ent comparing CP/CPPS patients and controls (Chisquare = 19.252, df = 8, P = 0.0231).
Signi¢cance tests of individual alleles
Analysis of individual alleles showed that the difference between CP/CPPS patients and controls was largely accounted for by three alleles, 9.5, 10 and 15. Based on previously reported DNA sequence data, the 9.5 allele is actually a mutant, 11 allele (11 repeats of 4 bp each) with a 6 bp deletion in sequence £anking the repeat [34] . Only 6 (1.4%) of 420 total subjects exhibited the 9.5 allele. Of these six patients, ¢ve were in the CP/CPPS group. Thus, 4.2% of the 120 CP/CPPS patients had the 9.5 allele compared to only 0.3% of the 300 controls (Chi-square = 8.944, df = 1, P = 0.0028). Of the 420 total subjects who had distinct alleles, 123 (29%) exhibited the 10 allele. These 123 subjects with the 10 allele included 35.8% of 120 CP/CPPS patients compared to 26.7% of 300 controls (Chi-square = 3.478, df = 1, P = 0.062). Of the 420 total subjects who exhibited distinct alleles, 10 had the 15 allele. All 10 were in the control group. Thus, the 15 allele was present in 3.3% of the 300 controls but in none of the 120 CP/CPPS cases (Chisquare = 4.098, df = 1, P = 0.0429). There were no signi¢cant di¡erences in the frequencies of the 8, 9, 11, 12, 13 and 14 alleles between cases and controls. Of these, alleles 8 and 9 were relatively rare ( 6 5%) in the overall population of 420 subjects.
Discussion
Our data suggest that certain men may have a genetic predisposition to develop CP/CPPS. Signi¢-cant associations of certain alleles at the X-linked PGK1 STR ¢t with the clinical observation that many CP/CPPS patients have blood relatives with prostatitis, particularly in their maternal pedigrees (http://prostatitis.freeservers.com). This potential predisposition may be located in a speci¢c region of the X chromosome near other sites that appear to be critical for prostate growth and development, as well as for development of some familial prostate cancers. The PGK1 gene is located within the DXS983D XS995 interval of GeneMap'99 at 94.4^97.4 cM. AR is in the adjacent interval, DXS991^DXS983 at 86.9^94.4 cM. Ordering of loci is still uncertain, but the distance between PGK1 and AR may be relatively short. We examined cross-over frequencies at the GenLink, Human Meiotic Map (http://www.genlink.wustl.edu/). Using the marker DXS1275 as a reference present in overlapping intervals, we calculated that there were two cross-over events between AR and PGK1 out of 227 jointly informative meioses. AR is the only obvious candidate for genitourinary tract e¡ects in this region of the chromosome, but there are almost certainly uncharacterized genes in the vicinity making it premature to assign our results to any known gene.
Literature searches revealed no previous reports suggesting a genetic predisposition to develop CP/ CPPS. However, patient interviews frequently suggest a¡ected relatives on the maternal side. Of 100 patients responding to a survey, 18% reported an a¥icted maternal grandfather compared with 9% who had paternal grandfathers with CP/CPPS. Of the same 100 patients, 14% reported maternal uncles with CP/CPPS while 0% reported CP/CPPS a¥icted paternal uncles. These observations are consistent with an X-linked predisposing factor(s) although much further work will be needed to con¢rm or deny this. Since the X chromosome has only a small region of homology with the Y chromosome, most X-linked genes lack compensatory homologues if there is a de¢cient or otherwise marginally active gene.
Males who are castrated or otherwise lose testicular function prior to puberty are termed eunuchs. Eunuchs have prostate glands but do not develop the major prostate diseases: benign prostatic hyperplasia, prostate cancer and CP/CPPS. These observations suggest that hormones produced by the testes, speci¢cally testosterone and, if 5-K reductase is active, dihydrotestosterone (dHT), may determine vulnerability to prostate diseases.
Hormones and their receptors play important roles in many stages of prostate development. In the second month of embryo development, placental human chorionic gonadotropin (hCG) induces Leydig cells at the genital ridge to secrete testosterone [38] . Testosterone, if converted to dHT by an active 5-K reductase, promotes masculinization of the bi-potential gonads in the third month of gestation, as well as promoting prostate di¡erentiation and masculinization of the external genital structures. Leydig cell testosterone secretion, while controlled by placental hCG during the critical stage of sexual di¡erentia-tion, is later controlled by fetal pituitary luteinizing hormone. Assuming a normal AR, dHT continues to promote prostate growth and masculinization at puberty. Defective genes have been described at virtually every stage of this developmental cascade [38] . De¢ciency in 5-K reductase or in the AR can lead to severe interruptions in genitourinary development early in life. Adult onset prostate diseases may re£ect subtle variations in the activities of some of the same genes that are crucial in early development. For these reasons, we investigated polymorphic variation, using the PGK1 STR, in the region of the X chromosome where AR resides.
Since the majority of men may eventually be affected by prostate disease, it is extremely di¤cult to identify an ideal control group for comparison with CP/CPPS patients. We elected instead to compare CP/CPPS cases with general clinical, control blood samples. Lifetime incidences of prostate diseases are still in dispute, but susceptible individuals in the control group would tend to reduce di¡erences between CP/CPPS and controls in this study. We previously demonstrated that the PGK1 STR allele size is somatically stable allowing comparisons of blood DNA in one population with prostate tissue DNA in another [34] .
Mitochondrial DNA sequences suggest that humans likely evolved from a very limited population [39, 40] . We reasoned that during this early bottle-neck in evolution, there was likely only one, or perhaps a few variants of AR, or another gene a¡ecting prostate development. Later, genetic drift would have led to lineages with slightly di¡erent susceptibilities to diseases such as CP/CPPS.
The results presented here are consistent with variations in the Xq11^Xq13 region, perhaps AR, or another gene, predisposing men to CP/CPPS. It seems unlikely that variants of the housekeeping enzyme, PGK1, contribute to CP/CPPS predisposition. Rather, the variant PGK1 STRs detected probably mark ancient human lineages that would, by chance, be expected to have subtle variations in AR or other gene activities.
While statistically signi¢cant, di¡erences at the 9.5, 15 alleles among CP/CPPS patients vs. controls were relatively subtle. The di¡erence for the 10 allele (P = 0.06) is marginal and technically only signi¢cant at 90% con¢dence. Currently, our CP/CPPS population was not strati¢ed for di¡erences such as family history of CP/CPPS. It is possible that populations selected for family history may exhibit more dramatic di¡erences in PGK1 STR allele types. Such studies are underway.
In addition to Xq11^Xq13, other regions of the X chromosome and of autosomes have been implicated in genetic predisposition to urologic diseases, particularly prostate cancer. Hypothesizing that variant genes implicated in other urologic diseases may play a role in prostate embryogenesis and development, we also plan to search for additional STRs in those regions. It is possible that if more associations are found, the combined typing of multiple STRs may provide practical diagnosis of a patient's vulnerability to CP/CPPS. This work is in progress.
In summary, potential genetic predispositions associated with the PGK gene, or another gene within Xq11^Xq13, such as AR, should be further investigated. This approach may provide important insights into the pathogenesis of CP/CPPS and other prostate diseases and open this ¢eld to powerful new genetic techniques. Work is in progress to scan the X chromosome with other polymorphic markers. Ultimately, it may prove possible to use such genetic information to predict a man's susceptibility to CP/ CPPS or his response to possible therapeutic interventions.
